GlassScriptPhysician profile
Cesar A Bravo
NPI 1245216530
$2,504.10
in general payments reported to CMS, 2019-2025
24 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.77 · 2020: $82.55 · 2021: $49.59 · 2022: $339 · 2023: $543 · 2024: $807 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.80 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $692.70 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $402.19 | 2022-2025 | |
| Amgen INC. | $206.29 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Mallinckrodt Hospital Products INC. | $151.53 | 2020-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $147.21 | 2023-2025 | |
| Horizon Therapeutics Plc | $144.04 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $129.57 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $95.40 | 2023-2025 | |
| Boston Scientific Corporation | $73.78 | 2021-2024 | Resolution 360 Clip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.68 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $50.84 | 2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $47.86 | 2024 | Purified Cortrophin Gel |
| Novo Nordisk INC | $47.60 | 2022-2025 | Ozempic |
| Outset Medical INC | $37.93 | 2023 | |
| Recor Medical INC | $37.08 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.50 | 2025 | Voyxact |
| Ascendis Pharma Endocrinology INC | $25.61 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $23.32 | 2024 | Ultomiris |
| Glaxosmithkline, LLC. | $22.14 | 2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $20.49 | 2023 | Lupkynis |
| Akebia Therapeutics INC | $16.23 | 2021 | |
| Lilly USA, LLC | $13.92 | 2023 | Jardiance |
| Fresenius USA Marketing, INC. | $13.18 | 2020 | |
| Vifor Pharma, INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Bravo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.